The safety, tolerability, pharmacokinetics, pharmacodynamics, and tumoricidal activity of CFT8634 are assessed in an ongoing phase 1/2 study in patients with locally advanced or metastatic SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors with unresectable or metastatic disease, who received ≥1 prior line of standard of care systemic therapy and for whom no other therapies are known to confer clinical benefit (NCT05355753). Here, SMARCB1 is linked to metastatic neoplasm.